DSIP

Overview

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It was first reported in the scientific literature in 1977 by Monnier and colleagues, who described its comparative properties in isolated and synthetic forms [1]. Its amino acid sequence was formally characterized in 1978 [2].

Human clinical research on DSIP peaked during the 1980s, with studies exploring its effects on insomnia and chronic pain. A final rigorous double-blind trial in 1992 found that its objective effects on sleep architecture were weak and likely driven by placebo variation, after which mainstream clinical research largely ceased [3].

Unlike Semax and Selank, DSIP has never been approved as a prescription drug in any jurisdiction. It is sold exclusively as a research chemical in modern markets.

Research Areas and Claims

DSIP is promoted in wellness and peptide communities for sleep improvement, pain reduction, and stress adaptation. The evidence base distinguishes strongly between early, positive (but poorly controlled) reports and the later double-blind findings:

• Sleep Regulation (Mixed Evidence): Early open-label studies showed promising sleep normalization in severe insomnia patients [7] and improved sleep architecture vs. placebo in a double-blind study [4]. However, the final rigorous 1992 double-blind trial concluded that objective sleep changes were very weak and DSIP is "not likely to be of major therapeutic benefit" for chronic insomnia [3].

• Chronic Pain (Pilot Evidence): A 1984 clinical pilot study found that IV DSIP administered over 10 injections produced a significant reduction in chronic pain episodes — suggesting neuromodulatory or analgesic properties beyond sleep regulation [8]. This finding has not been replicated in larger trials.

• Stress Adaptation / Anti-Anxiety (Not Well Supported): Claims of generalized stress adaptation and anti-anxiety effects are widely marketed in modern wellness contexts. These claims are largely anecdotal and are not supported by indexed human RCT data.

Mechanism of Action

1. Not a Direct Sedative: Unlike benzodiazepines or Z-drugs (zolpidem, etc.), DSIP does not directly suppress CNS activity to force sleep. It is described as a complex sleep-regulation modulator with phase-dependent effects: slight arousal may be observed in the first hour after injection, followed by sleep-promoting effects in the second hour [5].
2. Indirect Neuroendocrine Modulation: DSIP is believed to indirectly modulate neuroendocrine and CNS-linked signaling pathways — potentially interacting with endogenous opioid systems or stress-hormone (HPA axis) regulation — rather than acting through a direct, specific receptor [5][9].
3. Intranasal CNS Delivery: At least one human psychopharmacology study documented that intranasal DSIP administration increases the P300 event-related potential — a biomarker of cognitive processing — providing evidence that the intranasal route achieves meaningful CNS delivery [6].

Dosing Schedule (Clinical Context)

Clinical Trials & Evidence

Human clinical evidence for DSIP peaked during the 1980s and early 1990s. The five PubMed-indexed human studies below span the full arc of its clinical research — from early positive reports through the critical 1992 double-blind trial that effectively ended mainstream clinical interest.

Regulatory Status & Limitations

Vendor Directory

Data collected March 2026. Sorted by $/mg ascending within each section.

SC Injection — Finnrick A-Rated

Sold as kits. 99.99% purity; endotoxin-tested. Sale prices shown (regular prices ~45% higher).

SC Injection — Non-Finnrick

† Quantity-tiered pricing. Single-unit rate shown.

Sublingual Tablets & Nasal Spray — Pure Rawz Only

No Public Price / Not Available

References

1. [1]

   Monnier M, et al. "The delta sleep inducing peptide (DSIP). Comparative properties of the original and synthetic nonapeptide." Experientia. 1977. pubmed.ncbi.nlm.nih.gov/862769

2. [2]

   Schoenenberger GA. "The Delta EEG (Sleep)-Inducing Peptide (DSIP). XI. Amino acid analysis/sequence determination (DSIP characterization)." Pflugers Arch. 1978. pubmed.ncbi.nlm.nih.gov/568769

3. [3]

   Bes F, et al. "Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study." Neuropsychobiology. 1992. pubmed.ncbi.nlm.nih.gov/1299794

4. [4]

   Schneider-Helmert D. "Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia." Eur Neurol. 1987. pubmed.ncbi.nlm.nih.gov/3622582

5. [5]

   Schneider-Helmert D, Schoenenberger GA. "The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep." Experientia. 1981. pubmed.ncbi.nlm.nih.gov/7028502

6. [6]

   Hruz P, et al. "Intranasal administration of delta sleep-inducing peptide increases P300." J Clin Psychopharmacol. 2001. pubmed.ncbi.nlm.nih.gov/11763019

7. [7]

   Kaeser HE. "A clinical trial with DSIP." Eur Neurol. 1984. pubmed.ncbi.nlm.nih.gov/6391926

8. [8]

   Larbig W, et al. "Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study." Eur Neurol. 1984. pubmed.ncbi.nlm.nih.gov/6548970

9. [9]

   Kovalzon VM. "Delta sleep-inducing peptide (DSIP): a still unresolved riddle." J Neurochem. 2006. pubmed.ncbi.nlm.nih.gov/16539679